Archive

Balancing the response to covid-19

Written by Christine Clark | 18 Oct 2020

Article written by Christine Clark As politicians grapple with the idea of a lockdown or a more stringent lockdown GPs have called for an end to the ‘one-track’… read more.

Dozens of blood pressure drugs do not elevate risk of depression

Written by Bruce Sylvester | 9 Oct 2020

Article written by Bruce Sylvester Dozens of the most widely used blood pressure medications show no tendency to elevate risk of depression, Danish researchers report.

Pesco-Mediterranean diet, intermittent fasting may lower heart disease risk

Written by Charlie King | 7 Oct 2020

A Pesco-Mediterranean diet rich in plants, nuts, whole grains, extra-virgin olive oil, and fish and/or seafood is ideal for optimizing cardiovascular health, according to a cumulative review published… read more.

Hostility linked with higher risk of death after second heart attacks

Written by Charlie King | 5 Oct 2020

Heart attack patients who are sarcastic or irritable could be putting their health at risk, according to research published today in the European Journal of Cardiovascular Nursing, a journal… read more.

Depression, but not anxiety, linked with inflammation and metabolic change

Written by Charlie King | 4 Oct 2020

Anxiety and depression are often linked and assumed to be closely related, but now research has shown for the first time that depression and anxiety have different biochemical… read more.

Top-line results from the phase III CLARITY study evaluating pimavanserin for the adjunctive treatment of major depressive disorder.-Acadia Pharmaceuticals.

Written by MUOL News | 23 Jul 2020

Acadia Pharmaceuticals Inc. announced top-line results from its 298 patient Phase III CLARITY study which combined two identical, double-blind, placebo-controlled studies evaluating the efficacy, safety and tolerability of… read more.

Soleno Therapeutics announces top-line results from phase III trial of DCCR for treatment of Prader-Willi syndrome.

Written by MUOL News | 14 Jun 2020

Soleno Therapeutics, Inc. announced top-line results from the Company’s Phase III trial, DESTINY PWS (C601), evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for patients with Prader-Willi Syndrome… read more.

STRIDE-1 Phase III Trial of AXS 05 meets key secondary endpoints in depression.- Axsome Therapeutics

Written by MUOL News | 1 Apr 2020

Axsome Therapeutics announced that AXS 05 (bupropion + dextromethorphan) met key secondary endpoints in the STRIDE-1 trial by rapidly and statistically significantly improving symptoms of depression on the… read more.

DDW 2018: Quality of life for IBD patients

Written by Karen Ramirez | 2 Oct 2018

Inflammatory bowel disease can have a detrimental impact of health-related quality of life, and reducing the physical and psychological disease burden is an important therapeutic target. Patient-reported outcomes… read more.

DDW 2018: Choice in patient management

Written by Karen Ramirez | 2 Oct 2018

IBD specialists have more treatment options than ever before; yet the optimal use of many agents, old as well as new, remains to be defined. A plenary session… read more.

Denmark: 1 in 4 people leave work a year after a heart attack

Written by Gary Finnegan | 11 May 2018

One in four people leave their job within a year of returning to work after having a heart attack, according to a study from Denmark in the Journal… read more.

BSH 2017: Cancer-related chronic fatique – internet and digital technology solutions

Written by Karen Ramirez | 14 Apr 2017

Chronic, cancer-related fatigue (CRF) is associated with a sudden- onset, profound lack of energy that is not relieved by rest. It is different from the fatigue experienced by… read more.

« Previous 1 … 7 8 9 10 11 … 16 Next »

Archive

Subscribe for our mailing list

Follow Us